You are here: Industry Insights > Sirnaomics

News List

First Patient Dosed in STP705 Study Cutaneous Basal Cell Carcinoma Treatment americanpharmaceuticalreview
January 27, 2021
Sirnaomics announced dose administration for the first patient in a Phase 2a clinical study of the company's lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma.
Sirnaomics seals $105m Series D financing for RNAi therapeutics pharmaceutical-business-review
October 28, 2020
Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its USD$105 million Series D financing.
Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US PR Newswire
January 09, 2020
Patrick Lu, PhD, President and Chief Executive Officer of Sirnaomics, stated, "This collaborative effort between Sirnaomics and Innovent will be the first example of a combination strategy using an RNAi drug candidate together with an approved immune chec
Sirnaomics Receives FDA Clearance to Initiate Phase 2 Study of STP705 americanpharmaceuticalreview
December 21, 2018
Sirnaomics announced the U.S. Food and Drug Administration (FDA) has agreed to the company's proposed trial design for a Phase 2 clinical study to .....
Sirnaomics cleared to start first trial of RNAi lead in cancer fiercebiotech
August 20, 2018
Gene-silencing specialist Sirnaomics has been cleared to start trials of its STP705 drug in bile duct cancer, its first oncology indication.